24. Yeung J, Vender R, Turchin I, et al. Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors. J Am Acad Dermatol. 2021;84:1169-1171.
25. Gasslitter I, Kirsten N, Augustin M, et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019;311:421-424.
26. Kimmel G, Chima M, Kim HJ, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81:857-859.
27. Politou M, Afroditi Kleidona I, Pompou M, Giannoukos A. Twenty patients with moderate to severe psoriasis successfully treated with brodalumab after a failed treatment with secukinumab [AAD abstract 18501]. J Am Acad Dermatol. 2020;83(6; suppl):AB214.
28. Loft N, Bregnhøj A, Fage S, et al. Efficacy of treatment with brodalumab after treatment failure of previous interleukin 17A inhibitors in patients with psoriasis [AAD abstract 26580]. J Am Acad Dermatol. 2021;85(3; suppl):AB107.
29. Zhao S, Chadwick L, Mysler E, Moots RJ. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20:57.
30. Kerdel F, Michael Lewitt G, Drew S, Jacobson A. Long-term efficacy and safety in clinical trials of brodalumab by prior response to adalimumab. Poster presented at: Winter Clinical Dermatology Conference; January 16- 24, 2021; Virtual.
31. Bhatia N, Alexis A, Anbalagan N, Jacobson A. Long-term efficacy of brodalumab in patients with moderate-to-severe psoriasis who received prior biologics. Poster presented at: Innovations in Dermatology Virtual Spring Conference; March 16-20, 2021.
32. Menter A, Bettencourt M, Altman D, et al. Rates of complete skin clearance by prior adalimumab response in clinical trials of brodalumab. Poster presented at: Fall Clinical Dermatology Conference; October 29-November 1, 2020; Virtual.
33. Stelara [package insert]. Horsham, PA: Janssen Biotech, Inc; 2019.
34. Wu JJ. Contemporary management of moderate to severe plaque psoriasis. Am J Manag Care. 2017;23(21; suppl):S403-S416.
35. Gorelick J, Shrom D, Sikand K, et al. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey. Dermatol Ther (Heidelb). 2019;9:785-797.
36. Shahwan KT, Kimball AB. Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. Int J Womens Dermatol. 2016;2:151-153.
37. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80:43-53.
38. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80:27-40.
39. Blauvelt A, Papp KA, Lebwohl MG, et al. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017;77:372-374.
25. Gasslitter I, Kirsten N, Augustin M, et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019;311:421-424.
26. Kimmel G, Chima M, Kim HJ, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81:857-859.
27. Politou M, Afroditi Kleidona I, Pompou M, Giannoukos A. Twenty patients with moderate to severe psoriasis successfully treated with brodalumab after a failed treatment with secukinumab [AAD abstract 18501]. J Am Acad Dermatol. 2020;83(6; suppl):AB214.
28. Loft N, Bregnhøj A, Fage S, et al. Efficacy of treatment with brodalumab after treatment failure of previous interleukin 17A inhibitors in patients with psoriasis [AAD abstract 26580]. J Am Acad Dermatol. 2021;85(3; suppl):AB107.
29. Zhao S, Chadwick L, Mysler E, Moots RJ. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20:57.
30. Kerdel F, Michael Lewitt G, Drew S, Jacobson A. Long-term efficacy and safety in clinical trials of brodalumab by prior response to adalimumab. Poster presented at: Winter Clinical Dermatology Conference; January 16- 24, 2021; Virtual.
31. Bhatia N, Alexis A, Anbalagan N, Jacobson A. Long-term efficacy of brodalumab in patients with moderate-to-severe psoriasis who received prior biologics. Poster presented at: Innovations in Dermatology Virtual Spring Conference; March 16-20, 2021.
32. Menter A, Bettencourt M, Altman D, et al. Rates of complete skin clearance by prior adalimumab response in clinical trials of brodalumab. Poster presented at: Fall Clinical Dermatology Conference; October 29-November 1, 2020; Virtual.
33. Stelara [package insert]. Horsham, PA: Janssen Biotech, Inc; 2019.
34. Wu JJ. Contemporary management of moderate to severe plaque psoriasis. Am J Manag Care. 2017;23(21; suppl):S403-S416.
35. Gorelick J, Shrom D, Sikand K, et al. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey. Dermatol Ther (Heidelb). 2019;9:785-797.
36. Shahwan KT, Kimball AB. Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. Int J Womens Dermatol. 2016;2:151-153.
37. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80:43-53.
38. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80:27-40.
39. Blauvelt A, Papp KA, Lebwohl MG, et al. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017;77:372-374.
AUTHOR CORRESPONDENCE
Mark G. Lebwohl MD Lebwohl@aol.com
